NanoVita seed round completed, valuation at $10 million

NanoVita Seed Round: Share Health Research Data

DeSci project NanoVita has completed its seed round at a $10 million valuation. The news was announced on March 31, 2026. The funds will be used to build health data sharing infrastructure that combines nanotechnology, AI, and blockchain, with a focus on the research foundation for real-world data (RWD).

The project idea is: use nanotechnology and AI for biological data analysis, and use blockchain to manage data ownership rights. The DeSci space has been attracting funding recently, and the team is exploring paths beyond traditional research grants. NanoVita wants to bypass centralized institutions to make health data sharing easier.

The investors’ backgrounds span crypto and financial technology, indicating that institutions are betting on blockchain applications for healthcare scenarios. They are bullish on DeSci’s direction of using distributed technology to transform research and data circulation.

Q1: Health Blockchain Still Getting Funded

After receiving this round of funding, NanoVita will move forward with nanotechnology and AI R&D, and use blockchain to govern health data. In terms of timing, DeSci’s exploration at the intersection of biotechnology and blockchain is gaining momentum.

What NanoVita aims to build is a health research collaboration infrastructure that doesn’t rely on traditional institutions. CGV leads the round, and UNIVERSE-DIMENSIONAL SPACE PTE. LTD. (Singapore), Candaq Fintech Group, and Susie Ventures (BVI) participate as follow-on investors. This round only disclosed a $10 million valuation and didn’t say how much was actually raised—an operation that’s common for early Web3 projects.

The use of funds in this round:

• CGV leads the round, bringing resources from the crypto industry;
• UDS complements an international fintech background;
• Candaq and Susie Ventures have experience investing in blockchain;
• The money is mainly directed toward decentralized research applications combining nanotechnology and AI;
• The bet is that the DeSci protocol can compete with centralized solutions in the health data domain.

This round of financing happens against the backdrop of ongoing investment into health-focused Web3 projects. NanoVita’s entry point is “real-world health data + transparency.” So far, there’s no news about subsequent rounds or token plans; the focus is on foundational infrastructure in the seed stage.

Funds are intended to advance an open health research framework, with blockchain ensuring data integrity and traceability. This aligns with the broader DeSci trend of raising funds: projects are trying to combine new technologies with decentralized systems. Investors believe this protocol can complement transparent research infrastructure, but a specific timeline has not been published yet.

Compared with other DeSci projects, NanoVita’s integration at the AI biological analysis layer may bring differentiated tools; the valuation-based pricing structure fits common early Web3 financing conventions. Several crypto media outlets have consistent reporting angles regarding both the investors and the valuation.

As we near the end of Q1 2026, this seed round shows that the market still has interest in Web3’s niche verticals (especially health × AI). Whether it can be implemented depends on progress in ecosystem building and data-sharing capabilities. With diversified investors providing initial support, the funding environment for the DeSci direction remains relatively healthy in the short term.

Put simply: DeSci is still getting funded, and in Q1 the health blockchain space continues to see financing.

My view: It’s still an early-stage window—better suited for long-term builders and institutional capital, with few short-term trading signals. If you’re interested in DeSci infrastructure and the health data direction, getting in now and pursuing deep collaboration could be a better deal.